troleandomycin has been researched along with Disease Models, Animal in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, CD; Dworetzky, S; Fitzpatrick, WC; Harden, D; He, H; Knox, RJ; Newton, AE; Philip, T; Polson, C; Sinz, MW; Sivarao, DV; Sun, LQ; Tertyshnikova, S; Weaver, D; Wu, YJ; Yeola, S; Zoeckler, M | 1 |
| Allard, JL; Court, MH; Duan, SX; Gonzalez, FJ; Gorman, N; Greenblatt, DJ; Hao, Q; Hunt, JA; Jeffery, EH; Kostrubsky, V; Sinclair, JF; Sinclair, PR; Szakacs, JG; von Moltke, LL; Walton-Strong, BW; Wolf, KK; Wood, SG; Wrighton, SA | 1 |
| Brain, EG; Drewes, P; Gustafsson, K; Hecht, JE; Waxman, DJ; Yu, LJ | 1 |
| Fraser, T; Li, M; Wen, C; Whitworth, JA | 1 |
| Franklin, MR; Kushner, JP; Phillips, JD | 1 |
5 other study(ies) available for troleandomycin and Disease Models, Animal
| Article | Year |
|---|---|
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibiti
Topics: Administration, Oral; Animals; Biological Availability; Cell Line; Cinnamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Disease Models, Animal; Fluorine; Injections, Intravenous; Ion Channel Gating; KCNQ2 Potassium Channel; Male; Membrane Potentials; Migraine Disorders; Morpholines; Parietal Lobe; Patch-Clamp Techniques; Potassium Channels; Potassium Channels, Voltage-Gated; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2003 |
Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice.
Topics: Acetaminophen; Alanine Transaminase; Animals; Benzoquinones; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disease Models, Animal; Drug Synergism; Enzyme Induction; Enzyme Inhibitors; Ethanol; Glucuronides; Glutathione; Hydroxylation; Imines; Liver; Liver Diseases; Male; Mice; Mice, Knockout; Pentanols; Severity of Illness Index; Testosterone; Troleandomycin | 2007 |
In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Cyclophosphamide; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Disease Models, Animal; Enzyme Induction; Female; Gliosarcoma; Half-Life; Hydroxylation; Ifosfamide; Liver; Male; Microsomes, Liver; Phenobarbital; Rats; Rats, Inbred F344; Troleandomycin | 1999 |
Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism.
Topics: Adrenocorticotropic Hormone; Animals; Anti-Bacterial Agents; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Male; Mifepristone; Mineralocorticoid Receptor Antagonists; Potassium; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Sodium; Spironolactone; Troleandomycin | 1999 |
CYP3A-inducing agents and the attenuation of uroporphyrin accumulation and excretion in a rat model of porphyria cutanea tarda.
Topics: Animals; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Disease Models, Animal; Enzyme Induction; Female; Oxidoreductases, N-Demethylating; Porphyria Cutanea Tarda; Pregnenolone Carbonitrile; Rats; Rats, Inbred F344; Troleandomycin; Uroporphyrins | 2000 |